None listed
Conditions
Interventions
Drug : Arm A : DWCZP tablet 100mg, Clozaril tablet 100mg, Oral Administration
Arm B : Clozaril tablet 100mg, DWCZP tablet 100mg, Oral Administration
Sponsors
Dong Hwa Pharm
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Adult male or female within range of 20 to 60. - Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool). - Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time. - One who might be pregnant must get negative result for pregnancy test (urine or blood ß-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal liagtion or menopause are excluded. - One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.
Exclusion criteria
Exclusion criteria: - One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug. - WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml. - Administering hypertension drug or has orthostatic hypotension. - One who has clinical problem with kidney or liver and include following criteria: CCr 30 mg/dl; ALT ?? AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN. - Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc). - Record of Granulocytopenia or Myeloproliferative disorder in the past. - Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions. - Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody. - Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia. - Record of seizure in 1 year before sigining informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc). - One who consitantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period. - Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period. - One who cannot attend routine blood tests. - Bone marrow malfunction. - Mental illness, durg addicted or in coma. - One who has any kind of circulation imperfection and patient with depressed central nervous system. - Major kidney and heart problem(e.g. myocarditis). - Incuarable epilepsy. - Paralytic intestinal obstruction. - Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absortion deficiency, etc. - Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study. - One who had drugs that can affect on result of the study for past 10 days before the study start. - One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form. - Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form. - Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc). - One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax,ss of Clozapine in plasma;AUC0-12h,ss of Clozapine in plasma | — |
Secondary
| Measure | Time frame |
|---|---|
| Tmax,ss of Clozapine in plasma;Terminal half-life(t1/2) of Clozapine in plasma;Accumulation Rate(R) of Clozapine in plasma | — |
Countries
Korea, Republic of
Contacts
Public ContactWon-Myoung Bahk
The Catholic University of Korea, Yeouido St. Mary's Hospital
Outcome results
None listed